


**[<sup>125</sup>I]-[D-Trp<sup>6</sup>]-LUTEINIZING HORMONE-RELEASING HORMONE**

Product Number: NEX365

**LOT SPECIFIC INFORMATION**

<b>CALCULATED AS OF:</b>	13-May-2024
<b>LOT NUMBER:</b>	IZ61440
<b>SPECIFIC ACTIVITY:</b>	81.4 TBq/mmol 2200 Ci/mmol 56.7 MBq/μg 1532 μCi/μg

**Package Size Information**

<b>Package Size as of 14-Jun-2024</b>
<b>370 kBq 10 μCi</b>
<b>1.85 MBq 50 μCi</b>

**RADIOCHEMICAL PURITY** ≥ 95%**MOLECULAR WEIGHT:** ~1436.5

**PACKAGING:** [<sup>125</sup>I]-[D-Trp<sup>6</sup>]-LH-RH is lyophilized from a solution containing 0.04M sodium phosphate, 1M glycine, 0.2M NaCl, 0.25% BSA, 500 KIU/ml Trasylol® at pH 7.2. It is shipped ambient.

**STABILITY AND STORAGE:** The lyophilized [<sup>125</sup>I]-[D-Trp<sup>6</sup>]-LH-RH should be stored at 4°C or lower. Following reconstitution with distilled water to a concentration of approximately 50 μCi/ml on calibration date, aliquot and store at -20°C or lower. Under these conditions the product is stable and usable for at least six weeks after fresh lot date.

**SPECIFIC ACTIVITY:** The initial specific activity of [<sup>125</sup>I]-[D-Trp<sup>6</sup>]-LH-RH is 2200 Ci/mmol (81.4 TBq/mmol), 1532 μCi/μg (56.7 MBq/μg). Preparative HPLC is used to separate unlabeled luteinizing hormone-releasing hormone from [<sup>125</sup>I]-[D-Trp<sup>6</sup>]-LH-RH. Upon decay, [<sup>125</sup>I]-[D-Trp<sup>6</sup>]-LH-RH undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular or peptide fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on <sup>125</sup>I decay and decay catastrophe of <sup>125</sup>I labeled compounds are available.<sup>1-5</sup>

**RADIOCHEMICAL PURITY:** Initially greater than 95% radiochemically pure as determined by HPLC.

**PREPARATIVE PROCEDURE:** [D-Trp<sup>6</sup>]-LH-RH is radioiodinated with no carrier added <sup>125</sup>I using a modification of the Hunter and Greenwood method<sup>6</sup> and purified by reversed phase HPLC.

**AVAILABILITY:** [<sup>125</sup>I]-[D-Trp<sup>6</sup>]-LH-RH is routinely available from stock and is prepared fresh and packaged for shipment on the second Monday of each month. Please inquire for larger package sizes.

**APPLICATIONS:** [<sup>125</sup>I]-[D-Trp<sup>6</sup>]-LH-RH will be useful for receptor binding studies in cell lines and tissue cultures.<sup>7-9</sup>

**HAZARD WARNING:** This product contains a chemical (s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion or inhalation. It is irritating to the eyes, the skin and the respiratory tract.

**RADIATION UNSHIELDED:** 280mR/hr/mCi at vial surface.

## REFERENCES:

1. Doyle, V.M., Buhler, F.R., Burgisser, E., *Eur. J. Pharm.* 99 353 (1984).
2. Schmidt, J., *J. Biol. Chem.* 259 1660 (1984).
3. Loring, R.H., Jones, S.W., Matthews-Bellinger, J., Salpeter, M.M., *J. Biol. Chem.* 257 1418 (1982).
4. Berridge, M.S., Jiang, V.W., Welch, M.J., *Rad. Res.* 82 467 (1980).
5. Charlton, D.E., *Rad. Res.* 107 163 (1986).
6. Hunter and Greenwood, F.C., *Nature* 194 495 (1962).
7. Emmons, G., Schroder, B., Ortmann, O., Westphalen, S., Schulz, K.D., Schally, A.V., *J. Clin. Endocrin. Met.* 77 1458-64 (1993).
8. Srkalovic, G., Bokser, L., Radulovic, S. Kockut, E., Schally, A.V., *Endocrinology* 127 3052-60 (1990).
9. Milovanovic, S.R., Monje, E., Szepeshazi, K., Radulovic, S., Schally, A., *J. Cancer Res. Clin. Oncol.* 119 273-8 (1993).

## IODINE-125 DECAY CHART HALF LIFE=60 days

Radiations Gamma 35.5 keV (7%) , X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16
0	1	0.977	0.955	0.933	0.912	0.891	0.871	0.851	0.831
20	0.794	0.776	0.758	0.741	0.724	0.707	0.691	0.675	0.66
40	0.63	0.616	0.602	0.588	0.574	0.561	0.548	0.536	0.524
60	0.5	0.489	0.477	0.467	0.456	0.445	0.435	0.425	0.416
80	0.397	0.388	0.379	0.37	0.362	0.354	0.345	0.338	0.33
100	0.315	0.308	0.301	0.294	0.287	0.281	0.274	0.268	0.262
120	0.25	0.244	0.239	0.233	0.228	0.223	0.218	0.213	0.208

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL, WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

revvity

Revvity, Inc.  
940 Winter Street  
Waltham, MA 02451 USA

(800) 762-4000  
www.revvity.com

For a complete listing of our global offices, visit [www.revvity.com](http://www.revvity.com)  
Copyright ©2023, Revvity, Inc. All rights reserved.



<b>18</b>
0.812
0.645
0.512
0.406
0.322
0.256
0.203

oes not  
do not  
IS ALL  
IRAL OR  
/ITH THE

by

